Skip to main content
Top
Published in: AIDS Research and Therapy 1/2016

Open Access 01-12-2016 | Research

Sero-prevalence of HBV and associated risk factors among HIV positive individuals attending ART clinic at Mekelle hospital, Tigray, Northern Ethiopia

Authors: Letebrhan Weldemhret, Tsehaye Asmelash, Rashmi Belodu, Dawit Gebreegziabiher

Published in: AIDS Research and Therapy | Issue 1/2016

Login to get access

Abstract

Background

Because of the shared mean of transmission, hepatitis B virus (HBV) is one of an important cause of co-morbidity and mortality in peoples living with HIV/AIDS. Hence, the aim of this study was to determine the sero-prevalence of HBV infection and associated risk factors in HIV/AIDS positive individuals attending ART clinic at Mekelle hospital, Mekelle, Northern Ethiopia.

Methods

A cross sectional study was conducted from August to October 2014 in HIV/AIDS positive adult individuals. Socio-demographic data and other explanatory variables were collected from 508 study participants using pre-tested and structured questionnaire-based interviews. Serum hepatitis B surface antigen (HBsAg) was detected using commercially available rapid test and third generation enzyme-linked immunosorbent assay (ELISA). Bivariate and multivariate analysis, using SPSS V.20.0, were performed to assess the variables associated with HBV infection and P value less than 0.05 was considered as statistically significant.

Results

A total of 508 study participants, 305 females and 203 males were included in this study with the mean (+SD) age of 37.8 + 9.6. The sero-prevalence of HBsAg was 5.9 %. Male gender (AOR = 2.6, 95 % CI 1.2–5.7), multiple sexual partners (AOR = 4.2, 95 % CI 1.3–13.1) and CD4 count <200 cells/μl (AOR = 3.5, 95 % CI 1.1–11.2) were significantly associated with HBsAg positivity.

Conclusion

The prevalence of HBsAg was similar to the general population. However, HIV/AIDS positive individuals with reduced CD4 count, <200 cells/μl, showed a significant association with HBsAg seropositivity. Therefore, we recommended, all HIV/AIDS positive individuals should be screened for HBsAg during their follow for better treatment outcome and minimize risks of HBV transmission.
Literature
1.
go back to reference Liver EAftSot, Française SdPIdL. Short statement of the first European consensus conference on the treatment of chronic hepatitis C and B in HIV co-infected patients. Médecine et maladies infectieuses. 2005;35(3):109–20.CrossRef Liver EAftSot, Française SdPIdL. Short statement of the first European consensus conference on the treatment of chronic hepatitis C and B in HIV co-infected patients. Médecine et maladies infectieuses. 2005;35(3):109–20.CrossRef
2.
go back to reference Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in Sub-Saharan Africa: an association between highly prevalent infectious diseases. a systematic review and meta-analysis. Int J Infect Dis. 2010;14(12):e1024–31.CrossRefPubMed Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in Sub-Saharan Africa: an association between highly prevalent infectious diseases. a systematic review and meta-analysis. Int J Infect Dis. 2010;14(12):e1024–31.CrossRefPubMed
3.
go back to reference Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med. 2003;4(3):241–9.CrossRefPubMed Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med. 2003;4(3):241–9.CrossRefPubMed
4.
go back to reference Annie Luetkemeyer. Hepatitis B and HIV coinfection. HIV in site knowledge base chapter. Oct 2010. Annie Luetkemeyer. Hepatitis B and HIV coinfection. HIV in site knowledge base chapter. Oct 2010.
5.
go back to reference Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology. 2008;48(4):1062–9.CrossRefPubMed Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology. 2008;48(4):1062–9.CrossRefPubMed
6.
go back to reference Ott J, Stevens G, Groeger J, Wiersma S. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg sero-prevalence and endemicity. Vaccine. 2012;30(12):2212–9.CrossRefPubMed Ott J, Stevens G, Groeger J, Wiersma S. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg sero-prevalence and endemicity. Vaccine. 2012;30(12):2212–9.CrossRefPubMed
7.
go back to reference Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV–HBV international panel. AIDS. 2005;19(3):221–40.PubMed Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV–HBV international panel. AIDS. 2005;19(3):221–40.PubMed
8.
go back to reference Chun HM, Roediger MP, Hullsiek KH, Thio CL, Agan BK, et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis. 2012;205(2):185–93.PubMedCentralCrossRefPubMed Chun HM, Roediger MP, Hullsiek KH, Thio CL, Agan BK, et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis. 2012;205(2):185–93.PubMedCentralCrossRefPubMed
9.
go back to reference Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97–107.CrossRefPubMed Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97–107.CrossRefPubMed
10.
go back to reference Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis. 2008;197(Supplement 3):S279–93.CrossRefPubMed Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis. 2008;197(Supplement 3):S279–93.CrossRefPubMed
11.
go back to reference Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut. 2012;61(Suppl 1):i47–58.CrossRefPubMed Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut. 2012;61(Suppl 1):i47–58.CrossRefPubMed
12.
go back to reference Zenebe Y, Mulu W, Yimer M, Abera B. Sero-prevalence and risk factors of hepatitis B virus and human immunodeficiency virus infection among pregnant women in Bahir Dar city, Northwest Ethiopia: a cross sectional study. BMC Infect Dis. 2014;14(1):118.PubMedCentralCrossRefPubMed Zenebe Y, Mulu W, Yimer M, Abera B. Sero-prevalence and risk factors of hepatitis B virus and human immunodeficiency virus infection among pregnant women in Bahir Dar city, Northwest Ethiopia: a cross sectional study. BMC Infect Dis. 2014;14(1):118.PubMedCentralCrossRefPubMed
13.
go back to reference Dessie A, Abera B, Wale F. Sero-prevalence of major blood-borne infections among blood donars at Felege Hiwot referral hospital, Northwest Ethiopia. Ethiop J Health Dev. 2007;21(1):68–9.CrossRef Dessie A, Abera B, Wale F. Sero-prevalence of major blood-borne infections among blood donars at Felege Hiwot referral hospital, Northwest Ethiopia. Ethiop J Health Dev. 2007;21(1):68–9.CrossRef
14.
go back to reference Wondimeneh Y, Alem M, Asfaw F, Belyhun Y. HBV and HCV sero-prevalence and their correlation with CD4 cells and liver enzymes among HIV positive individuals at University of Gondar Teaching Hospital, Northwest Ethiopia. Virol J. 2013;10(1):1–8.CrossRef Wondimeneh Y, Alem M, Asfaw F, Belyhun Y. HBV and HCV sero-prevalence and their correlation with CD4 cells and liver enzymes among HIV positive individuals at University of Gondar Teaching Hospital, Northwest Ethiopia. Virol J. 2013;10(1):1–8.CrossRef
15.
go back to reference Balew M, Moges F, Yismaw G, Unakal C. Assessment of hepatitis B virus and hepatitis C virus infections and associated risk factors in HIV infected patients at Debretabor hospital, South Gondar, Northwest Ethiopia. Asian Pac J Trop Dis. 2014;4(1):1–7.PubMedCentralCrossRef Balew M, Moges F, Yismaw G, Unakal C. Assessment of hepatitis B virus and hepatitis C virus infections and associated risk factors in HIV infected patients at Debretabor hospital, South Gondar, Northwest Ethiopia. Asian Pac J Trop Dis. 2014;4(1):1–7.PubMedCentralCrossRef
16.
go back to reference Leech NL, Barrett KC, Morgan GA. SPSS for intermediate statistics: use and interpretation. California: Psychol Press; 2005. Leech NL, Barrett KC, Morgan GA. SPSS for intermediate statistics: use and interpretation. California: Psychol Press; 2005.
17.
go back to reference Hosmer DW Jr, Lemeshow S. Applied logistic regression. New York: Wiley; 2004. Hosmer DW Jr, Lemeshow S. Applied logistic regression. New York: Wiley; 2004.
18.
go back to reference Gelaw B, Mengitsu Y. The prevalence of HBV, HCV and malaria parasites among blood donor in Amhara and Tigray regional states. Ethiop J Health Dev. 2008;22(1):3–7.CrossRef Gelaw B, Mengitsu Y. The prevalence of HBV, HCV and malaria parasites among blood donor in Amhara and Tigray regional states. Ethiop J Health Dev. 2008;22(1):3–7.CrossRef
19.
go back to reference Ive P, MacLeod W, Mkumla N, Orrell C, Jentsch U, et al. Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial. PloS ONE. 2013;8(12):e74900.PubMedCentralCrossRefPubMed Ive P, MacLeod W, Mkumla N, Orrell C, Jentsch U, et al. Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial. PloS ONE. 2013;8(12):e74900.PubMedCentralCrossRefPubMed
20.
go back to reference Tsuchiya N, Pathipvanich P, Rojanawiwat A, Wichukchinda N, Koga I, et al. Chronic hepatitis B and C co-infection increased all-cause mortality in HAART-naive HIV patients in northern Thailand. Epidemiol Infect. 2013;141(09):1840–8.PubMedCentralCrossRefPubMed Tsuchiya N, Pathipvanich P, Rojanawiwat A, Wichukchinda N, Koga I, et al. Chronic hepatitis B and C co-infection increased all-cause mortality in HAART-naive HIV patients in northern Thailand. Epidemiol Infect. 2013;141(09):1840–8.PubMedCentralCrossRefPubMed
21.
go back to reference Alo M, Alhassan H, Saidu A, Ugah U, Umar F. CD 4 + T cell count in patients concomitantly infected with HIV and hepatitis B virus in Sokoto State, Nigeria. Am J Epidemiol Infect Dis. 2013;1(3):24–6. Alo M, Alhassan H, Saidu A, Ugah U, Umar F. CD 4 + T cell count in patients concomitantly infected with HIV and hepatitis B virus in Sokoto State, Nigeria. Am J Epidemiol Infect Dis. 2013;1(3):24–6.
22.
go back to reference Chen X, He J-M, Ding L-S, Zhang G-Q, Zou X-B, et al. Prevalence of hepatitis B virus and hepatitis C virus in patients with human immunodeficiency virus infection in Central China. Arch Virol. 2013;158(9):1889–94.CrossRefPubMed Chen X, He J-M, Ding L-S, Zhang G-Q, Zou X-B, et al. Prevalence of hepatitis B virus and hepatitis C virus in patients with human immunodeficiency virus infection in Central China. Arch Virol. 2013;158(9):1889–94.CrossRefPubMed
23.
go back to reference Baha W, Foullous A, Dersi N, They-they TP, Nourichafi N, et al. Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco. BMC Public Health. 2013;13(1):50.PubMedCentralCrossRefPubMed Baha W, Foullous A, Dersi N, They-they TP, Nourichafi N, et al. Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco. BMC Public Health. 2013;13(1):50.PubMedCentralCrossRefPubMed
24.
go back to reference Khan F, Shams S, Qureshi ID, Israr M, Khan H, et al. Hepatitis B virus infection among different sex and age groups in Pakistani Punjab. Virol J. 2011;8(1):225–9.PubMedCentralCrossRefPubMed Khan F, Shams S, Qureshi ID, Israr M, Khan H, et al. Hepatitis B virus infection among different sex and age groups in Pakistani Punjab. Virol J. 2011;8(1):225–9.PubMedCentralCrossRefPubMed
26.
go back to reference Chang JJ, Sirivichayakul S, Avihingsanon A, Thompson AJ, Revill P, et al. Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol. 2009;83(15):7649–58.PubMedCentralCrossRefPubMed Chang JJ, Sirivichayakul S, Avihingsanon A, Thompson AJ, Revill P, et al. Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol. 2009;83(15):7649–58.PubMedCentralCrossRefPubMed
27.
go back to reference Ikeh CK, Oboma Y, Ikeh PE. Patterns of CD4 + cells and liver enzymes and their correlation with prevalence of HBV and HCV among HIV positive individuals at Orlu Hospital Counseling and Testing Unit, Imo state, South-East Nigeria. Int J Curr Microbiol Appl Sci. 2014;3(4):296–303. Ikeh CK, Oboma Y, Ikeh PE. Patterns of CD4 + cells and liver enzymes and their correlation with prevalence of HBV and HCV among HIV positive individuals at Orlu Hospital Counseling and Testing Unit, Imo state, South-East Nigeria. Int J Curr Microbiol Appl Sci. 2014;3(4):296–303.
28.
go back to reference Van Bommel F, Wunsche T, Mauss S, Reinke P, Schurmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004;40(6):1421–5.CrossRefPubMed Van Bommel F, Wunsche T, Mauss S, Reinke P, Schurmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004;40(6):1421–5.CrossRefPubMed
29.
go back to reference Harania RS, Karuru J, Nelson M, Stebbing J. HIV, hepatitis B and hepatitis C coinfection in Kenya. AIDS. 2008;22(10):1221–2.CrossRefPubMed Harania RS, Karuru J, Nelson M, Stebbing J. HIV, hepatitis B and hepatitis C coinfection in Kenya. AIDS. 2008;22(10):1221–2.CrossRefPubMed
30.
go back to reference Isaakidis P, Mansoor H, Zachariah R, Da Silva EA, Varghese B, et al. Treatment outcomes in a cohort of patients with chronic hepatitis B and human immunodeficiency virus co-infection in Mumbai, India. Int Health. 2012;4(4):239–45.CrossRefPubMed Isaakidis P, Mansoor H, Zachariah R, Da Silva EA, Varghese B, et al. Treatment outcomes in a cohort of patients with chronic hepatitis B and human immunodeficiency virus co-infection in Mumbai, India. Int Health. 2012;4(4):239–45.CrossRefPubMed
31.
go back to reference Keith A. Starting HIV treatment at CD4 count above 500 reduces the risk of serious illness and death by 44%, African Temprano trial shows. Conference on Retroviruses and Opportunistic Infections (CROI 2015). Keith A. Starting HIV treatment at CD4 count above 500 reduces the risk of serious illness and death by 44%, African Temprano trial shows. Conference on Retroviruses and Opportunistic Infections (CROI 2015).
32.
go back to reference Erena AN, Tefera TB. Prevalence of hepatitis B surface antigen (HBsAg) and its risk factors among individuals visiting Goba General Hospital, South East Ethiopia, 2012. BMC Res Notes. 2014;7(1):833.PubMedCentralCrossRefPubMed Erena AN, Tefera TB. Prevalence of hepatitis B surface antigen (HBsAg) and its risk factors among individuals visiting Goba General Hospital, South East Ethiopia, 2012. BMC Res Notes. 2014;7(1):833.PubMedCentralCrossRefPubMed
Metadata
Title
Sero-prevalence of HBV and associated risk factors among HIV positive individuals attending ART clinic at Mekelle hospital, Tigray, Northern Ethiopia
Authors
Letebrhan Weldemhret
Tsehaye Asmelash
Rashmi Belodu
Dawit Gebreegziabiher
Publication date
01-12-2016
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2016
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/s12981-016-0090-2

Other articles of this Issue 1/2016

AIDS Research and Therapy 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.